Innogenetics presents research results for first Alzheimer biomarker test in blood
At the Alzheimer's Association's International Conference on Prevention of dementia, Innogenetics presented research results with the first commercial blood test for beta-amyloid protein. Beta-amyloid is one of the potential biomarkers for Alzheimer's disease. With this new test, the INNO-BIA plasma A forms, researchers can measure different forms of this Alzheimer biomarker from a simple blood sample. This could - in the long term and after further investigation - lead to improved and accelerated development of Alzheimer drugs and possibly to earlier diagnosis of the condition.
The degeneration of nerve cells and the abnormal accumulation of beta-amyloid and tau proteins in the brain, are the most important pathological hallmarks of the disease. Beta-amyloid forms appear to be especially useful biomarkers for Alzheimer's disease. Up to now, Alzheimer biomarkers were measured in cerebrospinal fluid, for which lumbar puncture is necessary. But the invasive nature of this procedure, has been a limiting factor for the widespread use of this approach.
Innogenetics has now developed a commercial test, the INNO-BIA plasma A forms, to track early markers of Alzheimer's in the blood. These markers are measured using xMAP® technology (Luminex Corp., Austin, TX). Research studies with 556 patients in Sweden and Germany have shown that the blood test yields important results. Apparently, patients presenting with early memory problems who are at higher risk for developing Alzheimer turn out to have significantly different levels of beta-amyloid forms in their blood compared to persons at lower risk to develop the disease.
Innogenetics now plans to accelerate plans for new performance evaluation studies with the new research test in order to obtain CE marking.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
PANalytical announced the opening of its new Regional Application Laboratory in Shanghai, China
Henry Ford's idea revisited in DNA copying
First view of hydrogen at the metal-to-metal hydride interface
Waters Corporation to Assist US EPA in the Analysis of Perfluorinated Compounds (PFCs) in Soil and Water - Latest CRADA Aimed at Developing Liquid Chromatography and Mass Spectrometry Methods for Measuring PFCs at Very Low Concentrations
ZEISS: High-Tech Drives Growth - Medical technology and industrial metrology business still on track for growth
Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games
Grace extends reach in China
Mapping nanoscale chemical reactions inside batteries in 3-D
Virtual human in HIV drug simulation
No excess baggage: Antarctic insect's genome, newly sequenced, is smallest to date - Researchers suggest bare-bones genome is adaptation to deep freeze
